Company news

Edesa Biotech, Inc. news in 2026

Edesa Biotech, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference

November 4, 2026

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

October 15, 2026

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

August 19, 2026

Edesa Biotech Announces Proposed Public Offering

August 19, 2026

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

August 13, 2026

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

June 11, 2026

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

June 4, 2026

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

May 18, 2026

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

May 14, 2026

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

March 31, 2026

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

March 25, 2026

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

February 24, 2026

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

February 13, 2026

Decks in 2026